http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shu Wang,Houpu Yang,Jiajia Guo,Miao Liu,Fuzhong Tong,Yingming Cao,Bo Zhou,Peng Liu,Lin Cheng,Fei Xie,Deqi Yang,Jiaqing Zhang 한국바이오칩학회 2011 BioChip Journal Vol.5 No.1
Neo-adjuvant chemotherapy for breast cancer substantially benefits patients who achieve pathological response. However, clinical or pathological response information can only be obtained a period of time after chemotherapy. The identification of novel bio-markers or the application of new technique that can be used to predict treatment response before che-motherapy would allow therapy to be tailored on an individual patient basis. The purpose of this study is to identify the chemo-sensitivity and chemo-resistance related proteins using antibody microarray profiling, and to develop a multi-protein predictive model for breast cancer. Total protein was extracted from core needle biopsy samples obtained from 15 patients before treatment with neo-adjuvant TA(combination of taxanes and anthracycline) chemotherapy. Protein profiling was analyzed by antibody microarray. 10 pati-ents were used as training set to develop the predictive model using the software PAM(prediction analysis of microarray). Another 5 patients were used as a validation set to test the model. In cross-validation, the mole-cular predictive model showed an accuracy of 90%, in independent validation, the model classified the cases with an accuracy of 80%. In conclusion, the proteomic predictive model has the potential to predict pathological response to neo-adjuvant TA chemotherapy.